Projects per year
Fingerprint
Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 7 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 1 Finished
-
Inhibition of Autophagy: A Novel Therapeutic Strategy for Advanced Solid Tumors
Mahalingam, D. & Giles, F. J.
7/17/09 → 6/30/13
Project: Research project
Research output
-
Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
De Souza, A., Tavora, F. A., Mahalingam, D., Munster, P. N., Safran, H. P., El-Deiry, W. S. & Carneiro, B. A., Oct 19 2020, In: Frontiers in immunology. 11, 595289.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Correction to: Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation (CardioVascular and Interventional Radiology, (2019), 42, 5, (700-711), 10.1007/s00270-019-02191-z)
Ali, R., Yang, Y., Antkowiak, M., Gabr, A., Mora, R., Abouchaleh, N., Asadi, A. A., Kulik, L., Ganger, D., Abecassis, M., Katariya, N., Mulcahy, M., Benson, A., Mahalingam, D., Thornburg, B., Mouli, S., Lewandowski, R. J., Salem, R. & Riaz, A., May 1 2020, In: Cardiovascular and Interventional Radiology. 43, 5, p. 806 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: A phase Ib study a C
Mahalingam, D., Wilkinson, G. A., Eng, K. H., Fields, P., Raber, P., Moseley, J. L., Cheetham, K., Coffey, M., Nuovo, G., Kalinski, P., Zhang, B., Arora, S. P. & Fountzilas, C., Jan 1 2020, In: Clinical Cancer Research. 26, 1, p. 71-81 11 p.Research output: Contribution to journal › Article › peer-review
Open Access17 Scopus citations -
Phase I and biomarker study of the wnt pathway modulator dkn-01 in combination with gemcitabine/ cisplatin in advanced biliary tract cancer
Goyal, L., Sirard, C., Schrag, M., Kagey, M. H., Eads, J. R., Stein, S., El-Khoueiry, A. B., Manji, G. A., Abrams, T. A., Khorana, A. A., Miksad, R., Mahalingam, D., Zhu, A. X. & Duda, D. G., Dec 2020, In: Clinical Cancer Research. 26, 23, p. 6158-6167 10 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours
Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Völkel, D., Youssef, A., de Jong, F. A. & Tsimberidou, A. M., Sep 1 2020, In: British Journal of Clinical Pharmacology. 86, 9, p. 1836-1848 13 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations
Press / Media
-
Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
11/9/20 → 11/10/20
6 items of Media coverage
Press/Media: Press / Media
-
Vigeo Therapeutics To Present New Phase 1/2 VT1021 Dose Escalation And Expansion Data At The Society For Immunotherapy Of Cancer's 2020 Annual Meeting
11/9/20
2 items of Media coverage
Press/Media: Press / Media
-
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
5/14/20
17 items of Media coverage
Press/Media: Press / Media
-
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting; Clinical response was associated with tumor-specific replication, PD-L1 upregulation, and CD8+ cell recruitment in multiple my
5/14/20
5 items of Media coverage
Press/Media: Press / Media
-
Oncolytics Biotech Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda in Patients with Advanced Pancreatic Adenocarcinoma
11/7/19
1 item of Media coverage
Press/Media: Press / Media